Phase 3Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-1)
A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation
- Sponsor
- GlaxoSmithKline (Industry)
- Enrolment
- 981 planned
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Depemokimab; Placebo
- Ages
- adults, older adults
- Registry
- NCT06959095
From the registry
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Primary outcomes
- Annualized Rate of Moderate/Severe Exacerbations